Samsung has announced that it will spend around KRW 450 trillion (around $355 billion) on semiconductor and biopharmaceutical segments over the next five years. The company will also invest in next-generation technologies to stay ahead of its competitors. The South Korean tech chaebol has increased its investment by 30% compared to its previous five-year plan of […]
Read MoreWhat do semiconductors and COVID-19 vaccines have in common? Nothing really, but Samsung Biologics reportedly wants to secure vaccine production orders as well as patented technologies from US-based pharmaceutical companies Pfizer and Moderna, and the Korean tech giant’s semiconductor expansion plans in the USA might be used as leverage. President Moon Jae-in will attend the […]
Read MoreSamsung Biologics announced earlier today that it has clinched a deal to manufacture a candidate treatment for the coronavirus treatment. The biopharmaceutical arm of Samsung Group has signed a $362.2 million contract with the U.S. drug firm Vir Biotechnology.The company will start full-scale production of candidate COVID-19 treatment that is known to quite powerful in neutralizing […]
Read More
